

Great Science. Deep Compassion. Real Impact.



At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders, including addiction, serious mental illness and sleep disorders. With our portfolio of marketed medicines and investigational pipeline candidates, we seek to make a meaningful difference in the way people manage these complex diseases.

Marketed Medicines

Our portfolio of proprietary commercial products focuses on chronic conditions that represent some of the most challenging health issues of our time. We currently market commercial products focused on these complex diseases:

- Alcohol Dependence
- Bipolar I Disorder
- Narcolepsy
- Opioid Dependence
- Schizophrenia


Company Info

- Founded: 1987
- Total Employees: Approx. 2,000 worldwide

Ireland
Corporate Headquarters

Massachusetts
Research & Development
Corporate Offices

Ohio
Manufacturing



Our Pipeline

Molecule & Proposed Indication(s)	Preclinical	Phase 1	Phase 2	Phase 3
Sodium Oxybate Extended-Release Oral Suspension <i>Idiopathic Hypersomnia</i>				
Olanzapine and Samidorphan <i>Schizophrenia and Bipolar I Disorder (Pediatric)</i>				
Alixorexton <i>Narcolepsy Type 1</i>				
<i>Narcolepsy Type 2</i>				
<i>Idiopathic Hypersomnia</i>				
ALKS 7290 <i>Attention-Deficit Hyperactivity Disorder</i>				
ALKS 4510 <i>Fatigue – Neurodegenerative Disorders*</i>				
Valiloxylate <i>Narcolepsy and Idiopathic Hypersomnia</i>				

*In patients with fatigue associated with multiple sclerosis and Parkinson's disease

Last updated: August 2026

The pipeline includes both investigational product candidates and investigational uses of approved products that have not been approved by a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority.





Responsibility

Corporate responsibility is inherent in our mission as an organization that actively works to support people living with complex and difficult-to-treat psychiatric and neurological disorders. We strive to manage our business in a manner that promotes transparent governance and strong ethics; maintains extensive patient, employee and other stakeholder engagement; and helps us grow our organization strategically, sustainably and responsibly.

Alkermes respects the culture, customs and values of the people in the communities in which we work and live. We seek to support and positively impact our communities through our grant programs, sponsorship contributions, donations and employee volunteer support.



“Our company is energized by the opportunity to make a positive impact – on patients living with complex neurological and psychiatric disorders, and on the communities in which we live and work”

-Richard Pops, Chairman and former CEO

An Award-Winning Employer



Alkermes is proud to be recognized as an employer of choice.

Connect With Us

[in linkedin.com/company/alkermes/](https://www.linkedin.com/company/alkermes/)
www.alkermes.com

Media Relations: media.info@alkermes.com
 Investor Inquiries: investor_relations@alkermes.com
 Business Development: busdev@alkermes.com

